Press release
North America
November 13, 2014

Evonik Corporation Announces New Distribution Agreements For Silica In U.S.

Evonik Corporation’s Inorganic Materials Business Unit has announced new agreements with The Cary Company and Dorsett & Jackson, Inc., to broaden distribution of its silica products in the U.S. Midwest and Western regions, respectively.

Previously representing Evonik’s silica product lines in Minnesota, Wisconsin, North Dakota, South Dakota, Northern Indiana, and portions of Iowa and Illinois, The Cary Company will now also cover all of Iowa, Illinois, Missouri, Kansas and Nebraska.

In addition to the territories of California, Oregon, Washington, Nevada and Arizona, Dorsett & Jackson, Inc., will represent Evonik’s silica product lines in Utah, Colorado, Wyoming, Montana, and Idaho.

The agreement includes ACEMATT® Matting Agents, SIPERNAT® and SIDENT® Precipitated Silica, AEROSIL® Fumed Silica, AEROXIDE® Mixed Metal Oxides, and AERODISP® Dispersions.

Walsh & Associates, Inc. had previously supported Evonik’s distribution of silica in these areas.

Evonik’s silica products are used in diverse applications including paints & coatings, adhesives & sealants, plastics, inks, silicone and life sciences.

For additional information about Evonik in North America, please visit our website: www.evonik.com/north-america. Please visit us on Facebook at www.facebook.com/EvonikNorthAmerica. Follow us on Twitter at http://twitter.com/EvonikN_America.

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2013 more than 33,500 employees generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.0 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.